Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

Neoadjuvant chemoimmunotherapy for muscle-invasive bladder cancer (MIBC) followed by risk-adapted therapy led to high rates ...

Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.

Shilpa Gupta, MD, discusses the key takeaways from the long-term outcomes of the JAVELIN Bladder 100 trial for community ...

GU ASCO annual meeting featured a session on the ABCs of antibody drug conjugates and a presentation by Dr. Di Maria Jiang discussing the targeting of bladder cancer with antibody drug conjugates. Dr.

The trial led by scientists at the Melanoma Institute of Australia has presented data that establishes that long-term disease ...

“It may therefore be that advanced bladder cancer is particularly sensitive to the specific combination of nivolumab and cisplatin,” suggested Dr Apolo. Overall, she said that the data from ...

Dose-dense MVAC plus nivolumab achieved an 84% metastases-free rate in muscle-invasive bladder cancer patients. Patients were stratified into active surveillance or intervention groups based on ...